Insilico Medicine’s Alex Zhavoronkov Earns Fourth Clarivate Highly Cited Researcher Honor in 2026
BOSTON, Nov. 18, 2026 — Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company using generative AI for drug discovery and development, today announced that its founder and CEO, Alex Zhavoronkov, PhD, has been named to Clarivate’s 2026 Highly Cited Researchers list in Pharmacology and Toxicology. The fourth recognition, following selections in 2022, 2024 and
